Document is current
Any future updates will be listed below
-
Authors
Geller, Jamarie A. https://orcid.org/0000-0001-9049-4400
Pacilio, Rachel https://orcid.org/0000-0001-6568-267X
Downey, Amanda E. https://orcid.org/0000-0002-5206-7798
Ragnhildstveit, Anya https://orcid.org/0000-0002-5796-3428
Raymond-Flesch, Marissa https://orcid.org/0000-0003-0037-8970
Knatz-Peck, Stephanie https://orcid.org/0000-0001-9421-9158
Gukasyan, Natalie https://orcid.org/0000-0003-3567-1421
- License Information
-
More Information
Article History
Received: 30 July 2025
Accepted: 27 April 2026
First Online: 14 May 2026
Declarations
: The authors have no financial interests to disclose. Jamarie Geller has been involved in two clinical trials involving the use of psilocybin-assisted psychotherapy for fibromyalgia and treatment-resistant depression at the University of Michigan. Stephanie Knatz-Peck is a senior clinical consultant for Compass Pathways, funder of the Phase 1 anorexia nervosa clinical trial noted in this manuscript. Natalie Gukasyan reports current research support from Reunion Neuroscience and Helus Pharma, and personal fees from Multidisciplinary Association for Psychedelic Studies, outside the submitted work. Marissa Raymond-Flesch reports receiving philanthropic support from private donors to conduct a study of psilocybin for the treatment of anorexia nervosa in young adults.
: The authors declare no competing interests.
